This HTML5 document contains 101 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n31http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n30http://linked.opendata.cz/resource/AHFS/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00426/identifier/wikipedia/
n6http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00426/identifier/pharmgkb/
n16http://linked.opendata.cz/resource/drugbank/dosage/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00426/identifier/bindingdb/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00426/identifier/pubchem-compound/
n8http://bio2rdf.org/drugbank:
n21http://linked.opendata.cz/resource/drugbank/drug/DB00426/identifier/pubchem-substance/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00426/identifier/kegg-drug/
admshttp://www.w3.org/ns/adms#
n26http://linked.opendata.cz/resource/drugbank/drug/DB00426/identifier/drugbank/
n10http://linked.opendata.cz/resource/drugbank/patent/
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00426/identifier/national-drug-code-directory/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n13http://www.drugs.com/cdi/
n9http://linked.opendata.cz/resource/drugbank/property/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00426/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n28http://linked.opendata.cz/resource/drugbank/drug/DB00426/identifier/chebi/
n18http://linked.opendata.cz/resource/atc/
n17http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00426
rdf:type
n3:Drug
n3:description
Famciclovir is a guanine analogue antiviral drug used for the treatment of various herpes virus infections, most commonly for herpes zoster (shingles). It is a prodrug form of penciclovir with improved oral bioavailability. Famciclovir is marketed under the trade name Famvir (Novartis).
n3:dosage
n16:271B4BDF-363D-11E5-9242-09173F13E4C5 n16:271B4BE0-363D-11E5-9242-09173F13E4C5 n16:271B4BE1-363D-11E5-9242-09173F13E4C5 n16:271B4BE2-363D-11E5-9242-09173F13E4C5 n16:271B4BE3-363D-11E5-9242-09173F13E4C5 n16:271B4BE4-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
10 hours
n3:indication
For the treatment of acute herpes zoster (shingles). Also for the treatment or suppression of recurrent genital herpes in immunocompetent patients and treatment of recurrent mucocutaneous herpes simplex infections in HIV infected patients.
n3:manufacturer
n4:271B4BD8-363D-11E5-9242-09173F13E4C5 n4:271B4BD7-363D-11E5-9242-09173F13E4C5
owl:sameAs
n8:DB00426 n14:DB00426
dcterms:title
Famciclovir
adms:identifier
n20:3324 n21:46507561 n22:0078-0366-15 n23:PA449585 n24:D00317 n25:3207 n26:DB00426 n27:50066502 n28:4974 n29:Famciclovir
n3:mechanismOfAction
Famciclovir undergoes rapid biotransformation to the active antiviral compound penciclovir, which has inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2) and varicella zoster virus (VZV). In cells infected with HSV-1, HSV-2 or VZV, viral thymidine kinase phosphorylates penciclovir to a monophosphate form that, in turn, is converted to penciclovir triphosphate by cellular kinases. In vitro studies demonstrate that penciclovir triphosphate inhibits HSV-2 DNA polymerase competitively with deoxyguanosine triphosphate. Consequently, herpes viral DNA synthesis and, therefore, replication are selectively inhibited.
n3:packager
n4:271B4BD0-363D-11E5-9242-09173F13E4C5 n4:271B4BD1-363D-11E5-9242-09173F13E4C5 n4:271B4BCE-363D-11E5-9242-09173F13E4C5 n4:271B4BCF-363D-11E5-9242-09173F13E4C5 n4:271B4BD4-363D-11E5-9242-09173F13E4C5 n4:271B4BD5-363D-11E5-9242-09173F13E4C5 n4:271B4BD2-363D-11E5-9242-09173F13E4C5 n4:271B4BD3-363D-11E5-9242-09173F13E4C5 n4:271B4BD6-363D-11E5-9242-09173F13E4C5 n4:271B4BCC-363D-11E5-9242-09173F13E4C5 n4:271B4BCD-363D-11E5-9242-09173F13E4C5
n3:patent
n10:5246937 n10:2176392 n10:2086756 n10:5840763
n3:routeOfElimination
Active tubular secretion contributes to the renal elimination of penciclovir.
n3:synonym
2-(2-(2-amino-9H-Purin-9-yl)ethyl)-1,3-propanediol diacetate BRL-42810 Famvir Famciclovirum 9-[4-Acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine Famciclovir FCV Acetic acid 2-acetoxymethyl-4-(2-amino-purin-9-yl)-butyl ester
n3:toxicity
Symptoms of overdose include constipation, diarrhea, dizziness, fatigue, fever, headache, nausea, and vomiting.
n3:volumeOfDistribution
* 1.08±0.17 L/kg [healthy male subjects following a single intravenous dose of penciclovir at 400 mg administered as a 1-hour intravenous infusion]
n17:hasAHFSCode
n30:08-18-32
n3:foodInteraction
Take without regard to meals.
n3:proteinBinding
20-25%
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Famciclovir.htm
n5:hasConcept
n6:M0168276
foaf:page
n13:famciclovir.html n31:famciclovir.htm
n3:IUPAC-Name
n9:271B4BE9-363D-11E5-9242-09173F13E4C5
n3:InChI
n9:271B4BEF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n9:271B4BEE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n9:271B4BEB-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n9:271B4BEC-363D-11E5-9242-09173F13E4C5
n3:SMILES
n9:271B4BED-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n9:271B4BE7-363D-11E5-9242-09173F13E4C5
n3:logP
n9:271B4C00-363D-11E5-9242-09173F13E4C5 n9:271B4BE5-363D-11E5-9242-09173F13E4C5 n9:271B4BE8-363D-11E5-9242-09173F13E4C5
n3:logS
n9:271B4BE6-363D-11E5-9242-09173F13E4C5
n17:hasATCCode
n18:J05AB09 n18:S01AD07
n3:H-Bond-Acceptor-Count
n9:271B4BF5-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n9:271B4BF6-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n9:271B4BF0-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n9:271B4BF1-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n9:271B4BF3-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n9:271B4BF2-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n9:271B4BF4-363D-11E5-9242-09173F13E4C5
n3:absorption
77 %
n3:affectedOrganism
Human Herpes Virus
n3:casRegistryNumber
104227-87-4
n3:category
n3:clearance
* 36.6 +/- 6.3 L/hr [healthy male] * 0.48 +/- 0.09 L/hr/kg [healthy male]
n3:containedIn
n11:271B4BDB-363D-11E5-9242-09173F13E4C5 n11:271B4BDC-363D-11E5-9242-09173F13E4C5 n11:271B4BD9-363D-11E5-9242-09173F13E4C5 n11:271B4BDA-363D-11E5-9242-09173F13E4C5 n11:271B4BDD-363D-11E5-9242-09173F13E4C5 n11:271B4BDE-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n9:271B4BFB-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n9:271B4BFD-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n9:271B4BFE-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n9:271B4BFF-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n9:271B4BFA-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n9:271B4BF9-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n9:271B4BFC-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n9:271B4BEA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n9:271B4BF7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n9:271B4BF8-363D-11E5-9242-09173F13E4C5